CompletedPHASE1, PHASE2NCT03765632
Efficacy and Safety of the Cryopreserved Formulation of OTL-101 in Subjects With ADA-SCID
Studying Severe combined immunodeficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Great Ormond Street Hospital for Children NHS Foundation Trust
- Principal Investigator
- Claire Booth, DrGreat Ormond Street Hospital NHS Foundation Trust
- Intervention
- Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells (OTL-101)(genetic)
- Enrollment
- 13 enrolled
- Eligibility
- 17 years · All sexes
- Timeline
- 2018 – 2022
Study locations (1)
- Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom
Collaborators
Orchard Therapeutics
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03765632 on ClinicalTrials.govOther trials for Severe combined immunodeficiency
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT05651113The Experience of Screening for SCIDKing's College London
- ENROLLING BY INVITATIONPHASE1, PHASE2NCT01852370Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency DiseasesPaul Szabolcs
- ENROLLING BY INVITATIONNCT01186913Natural History Study of SCID DisordersNational Institute of Allergy and Infectious Diseases (NIAID)